We are strongest when leadership timing directly impacts enterprise value — placing executives at the exact moments where quality of hire shapes regulatory trajectory, capital formation, and investor confidence.
We are strongest when leadership timing directly impacts enterprise value. These are the roles where early, precise placement has the greatest downstream effect on regulatory trajectory, capital formation, and investor confidence.
The CMO is the most capital-sensitive hire in early-stage biopharma. Scientific credibility, regulatory fluency, and investor-facing communication skills must align simultaneously — making timing and candidate calibration critical to downstream valuation events.
CFO placement is never just a finance function. At pivotal funding stages, the right CFO shapes the financial narrative, builds governance infrastructure, and positions the company for investor scrutiny — making the hire inseparable from capital strategy.
Establishing pharmacovigilance leadership at the right inflection point reduces regulatory exposure, signals operational maturity to partners and regulators, and protects the integrity of clinical programs under increasing complexity.
CSO placement requires alignment between scientific vision, modality depth, and the strategic narrative presented to licensing, partnership, or M&A counterparties. We identify scientists who can lead internally and represent credibly externally.
Leadership transitions at public companies demand executives with governance experience, investor fluency, and the operational credibility to execute on an accelerated regulatory and commercial path — where visibility and accountability are at their highest.
Commercial leadership hired too late creates launch risk. The right CCO must be in place early enough to build the commercial infrastructure, shape the market narrative, and establish payer and KOL relationships before the launch window opens.
A hire made too early or too late relative to a financing event, regulatory milestone, or public market inflection creates structural misalignment between the executive's skillset and what the company actually needs in that moment.
Clinical executives are evaluated not only for their scientific credentials but for the confidence they instill in FDA reviewers, venture partners, and institutional investors. Their presence on a slide deck or regulatory filing carries weight that extends far beyond their day-to-day responsibilities.
Every executive hire at a capital-constrained, milestone-driven company is a risk event. The wrong hire at a critical inflection point doesn't simply underperform — it consumes capital, delays timelines, and erodes investor confidence at precisely the moment when none of those outcomes are recoverable.
If your company is approaching a financing event, regulatory milestone, or leadership transition — let's have a conversation about what the right hire looks like at this moment.
Initiate a Mandate